Literature DB >> 23666469

Update on oxalate crystal disease.

Elizabeth C Lorenz1, Clement J Michet, Dawn S Milliner, John C Lieske.   

Abstract

Oxalate arthropathy is a rare cause of arthritis characterized by deposition of calcium oxalate crystals within synovial fluid. This condition typically occurs in patients with underlying primary or secondary hyperoxaluria. Primary hyperoxaluria constitutes a group of genetic disorders resulting in endogenous overproduction of oxalate, whereas secondary hyperoxaluria results from gastrointestinal disorders associated with fat malabsorption and increased absorption of dietary oxalate. In both conditions, oxalate crystals can deposit in the kidney leading to renal failure. Since oxalate is primarily renally eliminated, it accumulates throughout the body in renal failure, a state termed oxalosis. Affected organs can include bones, joints, heart, eyes, and skin. Since patients can present with renal failure and oxalosis before the underlying diagnosis of hyperoxaluria has been made, it is important to consider hyperoxaluria in patients who present with unexplained soft tissue crystal deposition. The best treatment of oxalosis is prevention. If patients present with advanced disease, treatment of oxalate arthritis consists of symptom management and control of the underlying disease process.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666469      PMCID: PMC3710657          DOI: 10.1007/s11926-013-0340-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  101 in total

1.  Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.

Authors:  John C Lieske; William J Tremaine; Claudio De Simone; Helen M O'Connor; Xujian Li; Eric J Bergstralh; David S Goldfarb
Journal:  Kidney Int       Date:  2010-08-25       Impact factor: 10.612

2.  Primary hyperoxaluria--the German experience.

Authors:  Bernd Hoppe; Kay Latta; Christian von Schnakenburg; Markus J Kemper
Journal:  Am J Nephrol       Date:  2005-06-15       Impact factor: 3.754

3.  Granulomatous interstitial nephritis after a jejunoileal bypass: an ultrastructural and histochemical study.

Authors:  R Verani; M Nasir; R Foley
Journal:  Am J Nephrol       Date:  1989       Impact factor: 3.754

4.  The action of pyridoxine in primary hyperoxaluria.

Authors:  D A Gibbs; R W Watts
Journal:  Clin Sci       Date:  1970-02       Impact factor: 6.124

5.  Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for Toxic Alcohols Study Group.

Authors:  J Brent; K McMartin; S Phillips; K K Burkhart; J W Donovan; M Wells; K Kulig
Journal:  N Engl J Med       Date:  1999-03-18       Impact factor: 91.245

Review 6.  Cell-crystal interactions and kidney stone formation.

Authors:  J C Lieske; S Deganello; F G Toback
Journal:  Nephron       Date:  1999       Impact factor: 2.847

7.  Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome.

Authors:  Christiaan S van Woerden; Jaap W Groothoff; Ronald J A Wanders; Jean-Claude Davin; Frits A Wijburg
Journal:  Nephrol Dial Transplant       Date:  2003-02       Impact factor: 5.992

Review 8.  Non-crystalline and crystalline rheumatic disorders in chronic kidney disease.

Authors:  Pasha Sarraf; Jonathan Kay; Anthony M Reginato
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 9.  Heart failure with mitral valve regurgitation due to primary hyperoxaluria type 1: case report with review of the literature.

Authors:  Luc Van Driessche; Annemieke Dhondt; Johan De Sutter
Journal:  Acta Cardiol       Date:  2007-04       Impact factor: 1.718

Review 10.  Hyperoxaluria in malabsorptive states.

Authors:  H Andersson; I Bosaeus
Journal:  Urol Int       Date:  1981       Impact factor: 2.089

View more
  16 in total

1.  Bone oxaloma-a localized manifestation of bone oxalosis.

Authors:  Eun Ji Choi; Choong Guen Chee; Wanlim Kim; Joon Seon Song; Hye Won Chung
Journal:  Skeletal Radiol       Date:  2019-11-25       Impact factor: 2.199

2.  Malabsorption syndrome as a rare cause of nephrocalcinosis.

Authors:  Rui Abreu; Cláudia Bento; Luís Oliveira; Teresa Morgado
Journal:  Clin Cases Miner Bone Metab       Date:  2017-02-10

3.  Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient.

Authors:  Matthew R D'Costa; Nelson S Winkler; Dawn S Milliner; Suzanne M Norby; LaTonya J Hickson; John C Lieske
Journal:  Am J Kidney Dis       Date:  2019-03-22       Impact factor: 8.860

4.  Psychopharmacology for medically ill adolescents.

Authors:  Brenda Bursch; Marcy Forgey
Journal:  Curr Psychiatry Rep       Date:  2013-10       Impact factor: 5.285

Review 5.  Oxalate nephropathy in systemic sclerosis: Case series and review of the literature.

Authors:  Colin B Ligon; Laura K Hummers; Zsuzsanna H McMahan
Journal:  Semin Arthritis Rheum       Date:  2015-07-02       Impact factor: 5.532

6.  Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease.

Authors:  Majuran Perinpam; Felicity T Enders; Kristin C Mara; Lisa E Vaughan; Ramila A Mehta; Nickolay Voskoboev; Dawn S Milliner; John C Lieske
Journal:  Clin Biochem       Date:  2017-07-29       Impact factor: 3.281

7.  Maize Oxalyl-CoA Decarboxylase1 Degrades Oxalate and Affects the Seed Metabolome and Nutritional Quality.

Authors:  Jun Yang; Miaomiao Fu; Chen Ji; Yongcai Huang; Yongrui Wu
Journal:  Plant Cell       Date:  2018-09-10       Impact factor: 11.277

8.  Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.

Authors:  Dawn S Milliner; Pierre Cochat; Sally-Anne Hulton; Jerome Harambat; Ana Banos; Bastian Dehmel; Elisabeth Lindner
Journal:  Pediatr Nephrol       Date:  2021-01-30       Impact factor: 3.714

9.  Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.

Authors:  Elizabeth C Lorenz; John C Lieske; Barbara M Seide; Julie B Olson; Ramila Mehta; Dawn S Milliner
Journal:  Am J Kidney Dis       Date:  2020-09-04       Impact factor: 8.860

Review 10.  Treatment of nongout joint deposition diseases: an update.

Authors:  Tristan Pascart; Pascal Richette; René-Marc Flipo
Journal:  Arthritis       Date:  2014-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.